-
Merck’s 25 billion blockbuster drug domestic cancellation approval, AbbVie once starred hepatitis C drug from the market...
Time of Update: 2021-06-11
Generic drugs are forcing the original drugs to be withdrawn from the market. On May 24, the State Food and Drug Administration issued a batch of drug registration certificate revocation announcements
-
16 provincial-level pharmaceutical groups have begun to purchase and report for volume!
Time of Update: 2021-06-11
According to feedback, the Shenzhen Municipal Medical Insurance Bureau issued a notification on the 27th: "Notice on Filling in the Pre-purchasing Volume of Related Drugs Procured by Provincial Pharmaceutical Groups in 2021", requiring the breakdown of medical insurance, relevant medical institutions, and designated retail pharmacies Fill in the unified online reporting system on the provincial platform.
-
Another listed pharmaceutical company transforms into healthcare!
Time of Update: 2021-06-11
Changed to "Jimin Medical", the company's full name and securities code remain unchanged, and the date of change of the securities abbreviation is June 4, 2021.
-
Jointly issued by the Drug Administration of the two provinces!
Time of Update: 2021-06-11
The party’s use of unqualified polyester/aluminum/polyethylene medicinal composite film (batch number 2003079) violated Article 2 of the "Management Measures for Packaging Materials and Containers in Direct Contact with Drugs" (Bureau Order No.
-
The fifth batch of nationally sourced two varieties were eliminated!
Time of Update: 2021-06-11
However, there are differences in the rules for determining the first-year contracted purchase amount for each product and region, for azithromycin injection, fluconazole injection, linezolid glucose injection, moxifloxacin eye drops, tinidazole oral regular-release dosage form, etc.
-
For severe alopecia areata!
Time of Update: 2021-06-11
Article source: Pharmaceutical GuanlanOn June 2, the China Drug Clinical Trial Registration and Information Disclosure Platform showed that Zejing Pharmaceuticals launched a Phase 3 clinical trial of Jacketinib Hydrochloride Tablets for the treatment of severe alopecia areata.
-
Selective JAK inhibitors receive FDA priority review qualification for treatment of myelofibrosis
Time of Update: 2021-06-11
On June 1, 2021, CTI BioPharma announced that the US FDA has accepted its new drug application (NDA) for the investigational oral kinase inhibitor pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia.
-
Qilu imatinib mesylate tablets will be approved soon
Time of Update: 2021-06-11
Recently, Qilu Pharmaceutical entered the administrative examination and approval stage with imatinib mesylate tablets reported for production in category 4 imitations.
At present, CSPC Ouyi, Hausen, and Novartis have approved the production of imatinib mesylate tablets in China.
-
Good news for patients with hyperammonemia, domestic sodium phenylbutyrate powder will be approved soon
Time of Update: 2021-06-11
A few days ago, the marketing application of Zhaoke Pharmaceutical's 3 generic drug sodium phenylbutyrate powder (the relevant acceptance number is CYHS1800114) entered the administrative review stage, and it is expected that it will be formally approved soon for the adjuvant treatment of carbamoyl phosphate synthase ( CPS), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (AS) deficiency caused by chronic urea cycle disorder (UCD) caused hyperammonemia.
-
The list of the 15 highest paid pharmaceutical company executives in the world in 2020 announced
Time of Update: 2021-06-11
In the past year, the epidemic has swept the world, and the salary of executives of multinational pharmaceutical companies involved in the development of vaccines and therapeutics has also been affected.
-
Summary of the review of the fifth batch of nationally-sourced varieties in May
Time of Update: 2021-06-11
On May 8, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Fifth Batch of National-organized Drug Centralized Procurement of Drug Information Collection Work".
-
Levofloxacin intermediates and APIs of East Asia Pharmaceuticals passed Japanese GMP certification
Time of Update: 2021-06-11
The company's GMP certification by PMDA can also promote the company's sales of levofloxacin APIs and intermediates in other overseas markets.
-
Two pharmaceutical companies in Hubei Province were punished for producing and selling counterfeit and inferior drugs!
Time of Update: 2021-06-11
, Ltd. Illegal facts: Shandougen (batch number: 190101) produced by Hubei Mengshi Traditional Chinese Medicine Decoction Pieces Co.
3. The Chinese medicine decoction piece sea breeze vine (batch number: 171001) produced by the company was tested by the Binzhou Food and Drug Inspection and Testing Center.
-
Beijing Tide Pharmaceutical won the annual charity model of the 2021 China Charity List
Time of Update: 2021-06-11
was awarded the honorary title of "2021 China Charity List Annual Charity Model" for its active performance and outstanding contribution during the new crown pneumonia epidemic.
-
The pediatric Chinese patent medicine market has shrunk TOP10 products who are the most resistant to stress?
Time of Update: 2021-06-11
Figure 1: The share of the seven subcategories of pediatric Chinese patent medicines in 2020 (unit: %) Source: Mi Nei Net Database In terms of subcategories, pediatric cold medications and pediatric cough and expectorant medications are the two subcategories with the largest proportions, both at the terminals of public medical institutions in China and physical pharmacies in cities in China, but they are also the two most affected by the epidemic.
-
The fifth round of national procurement of these pharmaceutical companies to enter
Time of Update: 2021-06-11
The fifth batch of national procurement, the competitive landscape continues to change, and many pharmaceutical companies enter the gameA number of pharmaceutical companies entered the fifth batch of
-
The rapid development report of the medical and health industry analyzes the challenges of public medical institutions
Time of Update: 2021-06-11
Specifically, at the policy level, the reform of payment methods and " purchasing with volume ", which are mainly related to disease diagnosis , have had a profound impact on the industry’s traditional commercial and Companies have entered the medical and health industry across borders.
-
The ranking of TOP10 antidepressants has changed!
Time of Update: 2021-06-11
Recently, Shanghai Shangyao Zhongxi Pharmaceutical's duloxetine hydrochloride enteric-coated tablets was approved for supplementary application, and it was the first company to have reviewed the product; Hainan Herui Pharmaceuticals used generic 4 types of venlafaxine hydrochloride to be produced.
-
The notice regarding the full implementation of the new drug application information on drug listing and open bargaining procurement is here!
Time of Update: 2021-06-11
On May 31, Shanghai Sunshine Pharmaceutical Purchasing Network released the information publicity (the thirteenth batch) of new drug applications for the full implementation of open drug bargaining procurement on the Internet.
-
Prices of these Chinese medicinal materials have risen under the epidemic
Time of Update: 2021-06-11
On the other hand, under the impact of a large amount of low-priced imported turmeric, Chinese pharmaceutical companies' demand for Sichuan turmeric has decreased, and production capacity has been affected.
